Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making

作者：Corentin J. Gosling, Miguel Garcia‐Argibay, Michele De Prisco, Gonzalo Arrondo, Anaël Ayrolles, S. Antoun, Serge Caparos, Ana Catalán, Pierre Ellul, Maja Dobrosavljevic, Luís C. Farhat, Giovanna Fico, Luis Eudave, Annabeth P. Groenman, Mikkel Højlund, Lucie Jurek, Mikaïl Nourredine, Vincenzo Oliva, Valeria Parlatini, Constantina Psyllou, Gonzalo Salazar de Pablo, Anneka Tomlinson, Samuel J. Westwood, Andrea Cipriani, Christoph U Correll, Dong Keon Yon, Henrik Larsson, Edoardo G. Ostinelli, Jae Il Shin, Paolo Fusar‐Poli, John P. A. Ioannidis, Joaquim Raduà, Marco Solmi, Richard Delorme, Samuele Cortese · 发表于：BMJ · 年份：2025 · DOI：10.1136/bmj-2025-085875 · 被引用次数：21 · 研究领域：Attention Deficit Hyperactivity Disorder、Neuroethics, Human Enhancement, Biomedical Innovations、Traumatic Brain Injury Research

OBJECTIVES: To assess the effects of and related evidence certainty of interventions for attention deficit/hyperactivity disorder (ADHD) across an individual's lifespan, and to develop a continuously updated web platform for people with lived experience of ADHD as a method to disseminate living evidence synthesis for shared decision making. DESIGN: Umbrella review and platform for shared decision making. DATA SOURCES: Six databases from inception to 19 January 2025. Study authors were contacted for additional information when necessary. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews that used meta-analyses of randomised controlled trials were eligible if they compared a drug or non-drug intervention with a passive control in individuals with a diagnosis of ADHD. Primary outcomes were severity of ADHD symptoms, analysed by rater type (clinician-rated, parent-rated, teacher-rated, or self-rated) and time point (short term (12 weeks, or study endpoint), medium term (26 weeks), and long term (52 weeks)),acceptability (participants dropping out for any reason), and tolerability (participants dropping out owing to any side effects). Secondary outcomes included daily functioning, quality of life, comorbid symptoms, and key side effects (decreased sleep and appetite). DATA SYNTHESIS: Eligible meta-analyses were re-estimated with a standardised statistical approach. Methodological quality was assessed using AMSTAR-2. Evidence certainty was evaluated using an algorithmi...